Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740529 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 803
- Enrollment target
NCT03740529 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 803 participants.
The verdict
NCT03740529, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 803 participants
- Enrollment target
Study Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Interventions
- DRUG Venetoclax
- DRUG Rituximab
- DRUG Pirtobrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03740529
The ClinicalTrials.gov registry entry for NCT03740529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 803 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loxo Oncology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT03740529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03740529 about?
NCT03740529 is a clinical study titled "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL". This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
What is the current status of trial NCT03740529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 803 participants. The study started on 2019-03-15. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT03740529?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT03740529?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.